At ASCO this year, we will share new data from our robust portfolio and pipeline of advanced therapeutic platforms in cancer and blood disorders, showcasing the impact of our bold science in research.

Media releases

Jun 02, 2023

  • Media Release

Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups

Apr 26, 2023

  • Media Release

Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
View more
3D Illustration of molecules

ASCO for HCPs

Novartis continues to pursue scientific breakthroughs with the ambition to transform lives and renew patients’ hopes for the future.

Learn more
Scientists working in the lab at night

Investor Event

June 04, 2023 | Chicago, USA
 

 

Watch the webcast
Download the presentation (PDF 1.2 MB)

Learn more
Scientist working in a lab with frozen elements

Progress and Optimism in Oncology Today

Vas Narasimhan, CEO of Novartis

Read Vas article on LinkedIn

Related topics

Cancer

At Novartis, we’re committed to unraveling the inner workings of cancer. We’re developing new therapies for a range of common and rare cancers, investing in diverse technology platforms and experimenting with combination approaches.

Therapeutic areas

At Novartis, we invest in the most promising frontiers of science, the most exciting innovations in the business of medicine, and the most significant healthcare needs.